Rank,Term name,P-value,Z-score,Combined score,Overlapping genes,Adjusted p-value,Old p-value,Old adjusted p-value,gene count
1,Monoamine Transport WP727,0.008029136201052677,16.54272043745728,79.81330478547873,"['TNFRSF11B', 'NOS1']",0.35631631438199773,0,0,2
2,BDNF-TrkB Signaling WP3676,0.008795215484985847,15.714285714285714,74.38431628951099,"['NTRK2', 'HOMER1']",0.35631631438199773,0,0,2
3,Synaptic signaling pathways associated with autism spectrum disorder WP4539,0.015013423127900641,11.633477633477634,48.84676923544845,"['NTRK2', 'HOMER1']",0.35631631438199773,0,0,2
4,Aflatoxin B1 metabolism WP699,0.02565617300372849,51.782051282051285,189.6761559678131,['AKR7A3'],0.35631631438199773,0,0,1
5,Cytosine methylation WP3585,0.02565617300372849,51.782051282051285,189.6761559678131,['TDG'],0.35631631438199773,0,0,1
6,Effects of nitric oxide WP1995,0.03196801418519005,38.833333333333336,133.70392130649088,['NOS1'],0.35631631438199773,0,0,1
7,NO metabolism in cystic fibrosis WP4947,0.044470835620774404,25.884615384615383,80.57678051207762,['NOS1'],0.35631631438199773,0,0,1
8,Macrophage markers WP4146,0.05066232313924578,22.184981684981686,66.16832245391451,['CD163'],0.35631631438199773,0,0,1
9,BMP2-WNT4-FOXO1 pathway in primary endometrial stromal cell differentiation WP3876,0.05066232313924578,22.184981684981686,66.16832245391451,['SMAD9'],0.35631631438199773,0,0,1
10,Pathways of nucleic acid metabolism and innate immune sensing WP4705,0.05066232313924578,22.184981684981686,66.16832245391451,['IRF3'],0.35631631438199773,0,0,1
11,Ciliary landscape WP4352,0.05308596613137961,3.698190789473684,10.85730634733813,"['POM121', 'TRAF3IP1', 'RANBP10']",0.35631631438199773,0,0,3
12,SARS coronavirus and innate immunity WP4912,0.05681419767979379,19.41025641025641,55.66801415848988,['IRF3'],0.35631631438199773,0,0,1
13,Serotonin Transporter Activity WP1455,0.06292670924306515,17.252136752136753,47.71569371744252,['NOS1'],0.35631631438199773,0,0,1
14,ERK Pathway in Huntington's Disease WP3853,0.06292670924306515,17.252136752136753,47.71569371744252,['NTRK2'],0.35631631438199773,0,0,1
15,Osteoclast Signaling WP12,0.06292670924306515,17.252136752136753,47.71569371744252,['TNFRSF11B'],0.35631631438199773,0,0,1
16,Osteoblast Signaling WP322,0.06900010633336734,15.525641025641026,41.51008717376762,['TNFRSF11B'],0.35631631438199773,0,0,1
17,15q13.3 copy number variation syndrome WP4942,0.07503463593826243,14.113053613053612,36.550063297842115,['TRPM1'],0.35631631438199773,0,0,1
18,Glycerophospholipid Biosynthetic Pathway WP2533,0.07503463593826243,14.113053613053612,36.550063297842115,['PIP5K1A'],0.35631631438199773,0,0,1
19,Fragile X Syndrome  WP4549,0.07541828165735998,4.6035141329258975,11.89872862581898,"['NTRK2', 'HOMER1']",0.35631631438199773,0,0,2
20,Angiopoietin Like Protein 8 Regulatory Pathway WP3915,0.07728851266067752,4.536420101637493,11.614187843793268,"['PTPN1', 'SHC3']",0.35631631438199773,0,0,2
21,Kynurenine Pathway and links to Cellular Senescence WP5044,0.08103054353065882,12.935897435897436,32.50699329223288,['NOS1'],0.35631631438199773,0,0,1
22,STING pathway in Kawasaki-like disease and COVID-19 WP4961,0.08698807306113845,11.939842209072978,29.156906753101484,['IRF3'],0.35631631438199773,0,0,1
23,Blood Clotting Cascade WP272,0.09290746700714188,11.086080586080586,26.342204348269092,['F11'],0.35631631438199773,0,0,1
24,Statin inhibition of cholesterol production WP430,0.0987889663015849,10.346153846153847,23.948959891824675,['APOC1'],0.35631631438199773,0,0,1
25,Urea cycle and associated pathways WP4595,0.0987889663015849,10.346153846153847,23.948959891824675,['NOS1'],0.35631631438199773,0,0,1
26,Type I interferon induction and signaling during SARS-CoV-2 infection WP4868,0.1046328104250699,9.698717948717949,21.892897611123825,['IRF3'],0.35631631438199773,0,0,1
27,Differentiation of white and brown adipocyte WP2895,0.1046328104250699,9.698717948717949,21.892897611123825,['SMAD9'],0.35631631438199773,0,0,1
28,Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380,0.1069605697110211,3.7217068645640072,8.319112819550357,"['NTRK2', 'SHC3']",0.35631631438199773,0,0,2
29,Imatinib and Chronic Myeloid Leukemia WP3640,0.11043923733344096,9.127450980392156,20.110419623680883,['SPRED2'],0.35631631438199773,0,0,1
30,TLR4 Signaling and Tolerance WP3851,0.11043923733344096,9.127450980392156,20.110419623680883,['IRF3'],0.35631631438199773,0,0,1
31,RAS and bradykinin pathways in COVID-19 WP4969,0.11043923733344096,9.127450980392156,20.110419623680883,['NOS1'],0.35631631438199773,0,0,1
32,7-oxo-C and 7beta-HC pathways WP5064,0.12194078403251489,8.165317139001349,17.181621416326045,['THEM5'],0.35631631438199773,0,0,1
33,Host-pathogen interaction of human coronaviruses - interferon induction WP4880,0.12194078403251489,8.165317139001349,17.181621416326045,['IRF3'],0.35631631438199773,0,0,1
34,SARS-CoV-2 mitochondrial interactions WP5038,0.12194078403251489,8.165317139001349,17.181621416326045,['IRF3'],0.35631631438199773,0,0,1
35,Base Excision Repair WP4752,0.12763637240576028,7.756410256410256,15.96711267417482,['TDG'],0.35631631438199773,0,0,1
36,Type I collagen synthesis in the context of Osteogenesis imperfecta WP4786,0.12763637240576028,7.756410256410256,15.96711267417482,['TNFRSF11B'],0.35631631438199773,0,0,1
37,Fluoropyrimidine Activity WP1601,0.12763637240576028,7.756410256410256,15.96711267417482,['TDG'],0.35631631438199773,0,0,1
38,Regucalcin in proximal tubule epithelial kidney cells WP4838,0.12763637240576028,7.756410256410256,15.96711267417482,['NOS1'],0.35631631438199773,0,0,1
39,mBDNF and proBDNF regulation of GABA neurotransmission WP4829,0.1332954807588141,7.386446886446887,14.885071410526159,['NTRK2'],0.35631631438199773,0,0,1
40,White fat cell differentiation WP4149,0.1332954807588141,7.386446886446887,14.885071410526159,['IRF3'],0.35631631438199773,0,0,1
41,Insulin Signaling WP481,0.13691280850940685,3.186323880201431,6.335721421098844,"['PTPN1', 'SHC3']",0.35631631438199773,0,0,2
42,Amyotrophic lateral sclerosis (ALS) WP2447,0.13891833973144233,7.05011655011655,13.9160065218235,['NOS1'],0.35631631438199773,0,0,1
43,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) WP2817,0.13891833973144233,7.05011655011655,13.9160065218235,['PTPN1'],0.35631631438199773,0,0,1
44,Cell migration and invasion through p75NTR WP4561,0.13891833973144233,7.05011655011655,13.9160065218235,['NTRK2'],0.35631631438199773,0,0,1
45,Disruption of postsynaptic signaling by CNV WP4875,0.14450517857059983,6.743032329988852,13.043991016819689,['HOMER1'],0.35631631438199773,0,0,1
46,CAMKK2  Pathway WP4874,0.15005622503861193,6.461538461538462,12.255892200640496,['NOS1'],0.35631631438199773,0,0,1
47,Toll-like Receptor Signaling related to MyD88 WP3858,0.15005622503861193,6.461538461538462,12.255892200640496,['IRF3'],0.35631631438199773,0,0,1
48,Fibrin Complement Receptor 3 Signaling Pathway WP4136,0.15557170554826383,6.202564102564103,11.540791746931871,['IRF3'],0.35631631438199773,0,0,1
49,NO/cGMP/PKG mediated Neuroprotection WP4008,0.16105184504174017,5.963510848126233,10.889543434080146,['NOS1'],0.35631631438199773,0,0,1
50,Circadian rhythm related genes WP3594,0.16615962395988548,2.8101088101088103,5.0436011718057365,"['RAI1', 'HOMER1']",0.35631631438199773,0,0,2
51,Oxysterols derived from cholesterol WP4545,0.16649686706068215,5.7421652421652425,10.294432032957323,['THEM5'],0.35631631438199773,0,0,1
52,Phosphoinositides metabolism WP4971,0.16649686706068215,5.7421652421652425,10.294432032957323,['PIP5K1A'],0.35631631438199773,0,0,1
53,Ras signaling WP4223,0.16845432735952112,2.784786641929499,4.959957367136862,"['NTRK2', 'SHC3']",0.35631631438199773,0,0,2
54,Neovascularisation processes WP4331,0.1719069937807884,5.5366300366300365,9.748907482497215,['SMAD9'],0.35631631438199773,0,0,1
55,Neural Crest Cell Migration in Cancer WP4565,0.1719069937807884,5.5366300366300365,9.748907482497215,['NTRK2'],0.35631631438199773,0,0,1
56,The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies WP4879,0.19320294257520615,4.842948717948718,7.961876106703066,['TNFRSF11B'],0.38343006742451013,0,0,1
57,SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039,0.19320294257520615,4.842948717948718,7.961876106703066,['IRF3'],0.38343006742451013,0,0,1
58,Cytosolic DNA-sensing pathway WP4655,0.19844187700040436,4.695804195804196,7.59433175198793,['IRF3'],0.38343006742451013,0,0,1
59,Phosphodiesterases in neuronal function WP4222,0.19844187700040436,4.695804195804196,7.59433175198793,['NOS1'],0.38343006742451013,0,0,1
60,TGF-beta Receptor Signaling WP560,0.2088191850478117,4.426739926739927,6.9335431845006426,['SMAD9'],0.3967564515908422,0,0,1
61,Novel intracellular components of RIG-I-like receptor (RLR) pathway WP3865,0.21395798260056315,4.303418803418803,6.635766904314953,['IRF3'],0.39924387932374855,0,0,1
62,TGF-beta receptor signaling in skeletal dysplasias WP4816,0.22413691470806937,4.076248313090418,6.096021963922895,['SMAD9'],0.39924387932374855,0,0,1
63,p53 transcriptional gene network WP4963,0.22413691470806937,4.076248313090418,6.096021963922895,['SESN1'],0.39924387932374855,0,0,1
64,Folate Metabolism WP176,0.22413691470806937,4.076248313090418,6.096021963922895,['NOS1'],0.39924387932374855,0,0,1
65,Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.23916176592247726,3.7770481550969355,5.403502166196026,['NOS1'],0.4130975956842789,0,0,1
66,RANKL/RANK signaling pathway WP2018,0.23916176592247726,3.7770481550969355,5.403502166196026,['TNFRSF11B'],0.4130975956842789,0,0,1
67,Non-small cell lung cancer WP4255,0.2538992681046217,3.5186480186480185,4.823424888636502,['EML4'],0.43087961444865286,0,0,1
68,DNA damage response WP707,0.2587488542975002,3.4401709401709404,4.650758019699691,['SESN1'],0.43087961444865286,0,0,1
69,RAC1/PAK1/p38/MMP2 Pathway WP3303,0.2635673150621075,3.3651059085841695,4.487188623564421,['NOS1'],0.43087961444865286,0,0,1
70,Acute viral myocarditis WP4298,0.2683548475952136,3.293235133660666,4.332070072651467,['NOS1'],0.43087961444865286,0,0,1
71,miRNA regulation of DNA damage response WP1530,0.2683548475952136,3.293235133660666,4.332070072651467,['SESN1'],0.43087961444865286,0,0,1
72,Leptin signaling pathway WP2034,0.27783791070949426,3.1582940868655154,4.044882160843979,['PTPN1'],0.43388386056003214,0,0,1
73,Head and Neck Squamous Cell Carcinoma WP4674,0.27783791070949426,3.1582940868655154,4.044882160843979,['SESN1'],0.43388386056003214,0,0,1
74,ErbB signaling pathway WP673,0.2871995968864272,3.0339366515837103,3.7850721508866942,['SHC3'],0.44244262223044195,0,0,1
75,EGFR Tyrosine Kinase Inhibitor Resistance WP4806,0.2964414400181366,2.9189646831156266,3.5491854582990845,['SHC3'],0.45059098882756765,0,0,1
76,Alzheimer's disease WP2059,0.301017894485678,2.864672364672365,3.4392842920061772,['NOS1'],0.451526841728517,0,0,1
77,Prolactin Signaling Pathway WP2037,0.30556495476834095,2.812354312354312,3.334307319272615,['PTPN1'],0.4523948680985827,0,0,1
78,Toll-like Receptor Signaling Pathway WP75,0.31008280725124393,2.761904761904762,3.2339581917360536,['IRF3'],0.45319794905951033,0,0,1
79,Apoptosis WP254,0.3145716370669725,2.713225371120108,3.137963025815047,['IRF3'],0.45393881804601094,0,0,1
80,B Cell Receptor Signaling Pathway WP23,0.3278658258278823,2.576923076923077,2.8736578871700558,['PIP5K1A'],0.4636478733947868,0,0,1
81,Genes related to primary cilium development (based on CRISPR) WP4536,0.3365868492526337,2.4933829611248965,2.715042380917791,['TRAF3IP1'],0.4636478733947868,0,0,1
82,Integrin-mediated Cell Adhesion WP185,0.3409053687161496,2.4536019536019538,2.6404446043394376,['SHC3'],0.4636478733947868,0,0,1
83,Complement system WP2806,0.3494593095127674,2.3777120315581852,2.4998506973372723,['F11'],0.4636478733947868,0,0,1
84,DNA Repair Pathways Full Network WP4946,0.3536950820382754,2.3414918414918415,2.433559504872575,['TDG'],0.4636478733947868,0,0,1
85,Pathways in clear cell renal cell carcinoma WP4018,0.3536950820382754,2.3414918414918415,2.433559504872575,['PGBD5'],0.4636478733947868,0,0,1
86,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.3539469479888125,1.6308954203691046,1.6938614246485688,"['CAB39L', 'NOS1']",0.4636478733947868,0,0,2
87,Wnt signaling WP428,0.3579036215679056,2.3063528511289704,2.369758048148398,['PRICKLE2'],0.4636478733947868,0,0,1
88,Pathways Regulating Hippo Signaling WP4540,0.3579036215679056,2.3063528511289704,2.369758048148398,['NTRK2'],0.4636478733947868,0,0,1
89,ESC Pluripotency Pathways WP3931,0.3703675655559604,2.206959706959707,2.192083355266718,['SMAD9'],0.46401579971647516,0,0,1
90,Apoptosis Modulation and Signaling WP1772,0.3744688909992607,2.1756951968219576,2.1370690956385827,['TNFRSF11B'],0.46401579971647516,0,0,1
91,Male infertility WP4673,0.3744688909992607,2.1756951968219576,2.1370690956385827,['NOS1'],0.46401579971647516,0,0,1
92,Osteoblast differentiation WP4787,0.3744688909992607,2.1756951968219576,2.1370690956385827,['SMAD9'],0.46401579971647516,0,0,1
93,Hippo-Merlin Signaling Dysregulation WP4541,0.39852870161885806,2.0051615051615053,1.84469997804525,['NTRK2'],0.482938622582235,0,0,1
94,Ebola Virus Pathway on Host WP4217,0.40244885215186255,1.9792899408284024,1.8015244990670052,['IRF3'],0.482938622582235,0,0,1
95,Endoderm differentiation WP2853,0.40244885215186255,1.9792899408284024,1.8015244990670052,['SESN1'],0.482938622582235,0,0,1
96,Spinal Cord Injury WP2431,0.4140585716850105,1.9055080721747388,1.6801776222909828,['NOS1'],0.4911152497704693,0,0,1
97,Regulation of toll-like receptor signaling pathway WP1449,0.4178787651555747,1.8821138211382114,1.642264621260006,['IRF3'],0.4911152497704693,0,0,1
98,Ectoderm Differentiation WP2858,0.4254455277827245,1.836996336996337,1.5699307940500977,['TNFRSF11B'],0.49490602211459783,0,0,1
99,Metapathway biotransformation Phase I and II WP702,0.43291516189199436,1.7939773404889683,1.5019420502001781,['AKR7A3'],0.49616844269683,0,0,1
100,Chemokine signaling pathway WP3929,0.43661394099830086,1.773209549071618,1.469469223321563,['SHC3'],0.49616844269683,0,0,1
101,Hepatitis B infection WP4666,0.4402888984115722,1.7529137529137528,1.4379575373727558,['IRF3'],0.49616844269683,0,0,1
102,Regulation of Actin Cytoskeleton WP51,0.4439401855708479,1.7330740420628061,1.407369539386544,['PIP5K1A'],0.49616844269683,0,0,1
103,Mesodermal commitment pathway WP2857,0.4511723501840804,1.6947027331642717,1.3488238384804914,['SESN1'],0.4993558050581084,0,0,1
104,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways WP706,0.46884895340344557,1.6057692307692308,1.2163294433154785,['NTRK2'],0.5139305835383923,0,0,1
105,Breast cancer pathway WP4262,0.47576113437191386,1.5727367870225013,1.168290802868353,['SHC3'],0.5165406601752207,0,0,1
106,Vitamin D Receptor Pathway WP2877,0.48596320510876573,1.5256410256410255,1.100936689031546,['TNFRSF11B'],0.5226396734188612,0,0,1
107,Myometrial relaxation and contraction pathways WP289,0.49265542360608633,1.495767986059248,1.0589218965188314,['NOS1'],0.5248852176737742,0,0,1
108,Ciliopathies WP4803,0.5636987388964482,1.2203907203907205,0.6995710664539276,['TRAF3IP1'],0.5925426281462759,0,0,1
109,"GPCRs, Class A Rhodopsin-like WP455",0.5665539163854744,1.2106803957197658,0.6878880537708266,['OR6A2'],0.5925426281462759,0,0,1
110,Focal Adhesion WP306,0.5750092218319441,1.1824457593688362,0.6543290643130267,['SHC3'],0.5959186480803785,0,0,1
111,MAPK Signaling Pathway WP382,0.6510957734167804,0.9583333333333334,0.41121942478514073,['NTRK2'],0.6673685430749868,0,0,1
112,IL-18 signaling pathway WP4754,0.6556603230210397,0.946343779677113,0.39946346717023234,['TNFRSF11B'],0.6673685430749868,0,0,1
113,PI3K-Akt signaling pathway WP4172,0.7457958530090797,0.7342209072978304,0.21534946769239524,['NTRK2'],0.752395816310045,0,0,1
114,VEGFA-VEGFR2 Signaling Pathway WP3888,0.8369590236694316,0.5522144522144522,0.0982832198067396,['PTPN1'],0.8369590236694316,0,0,1
